Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' dTpa Booster Vaccine (263855) (Boostrix) Administered as a Booster Dose in Healthy Russian Subjects
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2018
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.
- 30 Aug 2018 Planned End Date changed from 29 Aug 2018 to 3 Sep 2018.
- 30 Aug 2018 Planned primary completion date changed from 29 Aug 2018 to 3 Sep 2018.